Value Creation
Portfolio Ops
Operating Partners

Find revenue execution risk before it becomes a board surprise.

Most value creation plans assume the sales system can carry the growth plan. The risk is usually hidden earlier — pipeline quality, qualification, forecast discipline, the weekly rhythm. We help you spot it, choose the intervention, and install the rhythm that closes the gap.

Not more portfolio support. Earlier visibility and cleaner intervention logic.

Book an investor call

The four patterns we look for

1
Demand

Is there enough of the right pipeline?

2
Efficiency

Does it convert and move?

3
Control

Can management trust the number?

4
Expansion

Is growth becoming repeatable?

1

Pre-deal

Is execution risk priced into the thesis? Risk banding and an early-warning read.

2

Hold period

Is the system carrying the plan? Closing OS Install plus modules where needed.

3

Exit readiness

Can the revenue story stand up to diligence? Forecast and cadence packs.

Not more portfolio support. Earlier visibility and cleaner intervention logic.

The Problem

Most portfolio growth plans don't fail because the ambition was wrong. They fail because the commercial system underneath the plan is not clear enough to inspect. Pipeline is counted before it's qualified. Forecasts rely too much on seller confidence. Deal risk appears too late. Managers have no common rhythm for correction. By the time the miss is visible, the best intervention window has often passed.

Who it is for

  • Value creation leads

  • Portfolio ops teams

  • Investment teams

  • Operating partners

  • Chairs / operating partners

  • CEOs / CROs in portfolio companies

The four patterns we look for

Demand

Is there enough of the right pipeline?

    Efficiency

    Does it convert and move?

      Control

      Can management trust the number?

        Expansion

        Is growth becoming repeatable?

          Where we plug in across the investment lifecycle

          Stage
          Investor question
          What we do
          Outputs
          Pre-deal
          Is commercial execution risk priced into the thesis?
          Growth Potential Score / execution-risk review
          Risk banding, triage view, early-warning report
          First 90 days
          What needs fixing or building first?
          5 Days to Scale
          GTM blueprint, 90-day plan, evidence tests
          Hold period
          Is the system carrying the growth plan?
          Closing OS Install + modules where needed
          Stage architecture, playbooks, CRM & AI sales workflow integration, weekly cadence, inspection rhythm
          Exit readiness
          Can the revenue story stand up to diligence?
          Run stabilisation
          Forecast pack, operating cadence pack, evidence of repeatability

          Operators who have carried the number

          Maria Scheifler
          US Operating Partner

          • $500K+ ARR pipeline in 60 days

          • 12× deal size; 70% pipeline via partners

          Russell Palmer
          Operating Partner

          • Scaled Pega ARR $9m → $54m (6× growth)

          • Doubled Virtalis ARR £4m → £8m in 2yrs

          ‍Laurie Mascott
          Operating Partner

          • Grew Concentra £0 → £19m ARR in 4yrs

          • Drove ChatLingual to 50% of global revenue in 18 mos

          Douglas Mancini
          Operating Partner

          • 70% Growth in Okta large Enterprise year on year

          • Doubled Critizr MRR, open new markets - UKI, DACH

          Erlend Asker
          Operating Partner

          • 7 % utilisation uplift unlocked €10 m+ margin at IFS

          • Grew €34 m services unit 4 out of 5 yrs; twice “global best of class"

          Marc Sabatini
          US Operating Partner

          • Co-founded and grew Aqfer; built repeatable GTM motions.

          • US CRO; designs and runs full-funnel GTM for scale.

          Joao Pedro Moniz Barreto
          Operating Partner

          • CrossVista: €400K → €1.9M (5×); 17 enterprise wins (68% win rate)

          • SI + retention: 30%+ pipeline via Accenture/Cognizant/Capgemini; 90% GRR (25 accounts)

          Andy Reid
          Operating Partner

          • Led €200m EMEA P&L at Deutsche Bank (17 markets)

          • Returned Tungsten sales to +18% YoY; scaled Bleckwen pipeline €7m→€35m.

          Frequently asked questions

          How does Closing Foundry help investors and portfolio teams?

          Closing Foundry helps investors and portfolio teams identify revenue execution risk early, translate value creation plans into practical commercial interventions and install the operating rhythm needed to make commercial progress inspectable. The work connects investment thesis to pipeline reality.

          What revenue execution risks do you look for?

          The most common risks are weak ICP focus, inconsistent qualification, stage definitions that are not evidence-based, single-threaded deals, a pipeline that looks larger than it is, founder-dependent selling, weak manager inspection and forecast confidence that is not supported by buyer evidence. Most are created upstream, long before quarter-end.

          What does an investor diagnostic include?

          The diagnostic reviews the commercial target, pipeline reality, deal control, forecast confidence, sales process, team capability, CRM truth and the operating rhythm behind the number. The output is a clear view of execution risk and priority order for intervention, designed to be shared at portfolio or board level.

          Want to see where execution risk is hiding in the portfolio?

          Bring one portfolio company, one investment thesis, or one recurring pattern you are seeing across the portfolio.

          We'ill help you work out where the commercial system may be under strain, what evidence to inspect first, and whether the right next step is a diagnostic, 5 Days to Scale, Closing OS Install or no external support.

          Book investor call